Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
14/08/26	₩1,705.00	+0.77%	14,548
13/08/26	₩1,692.00	+0.06%	3,344
12/08/26	₩1,691.00	-0.59%	2,679
11/08/26	₩1,701.00	+0.95%	6,356
10/08/26	₩1,685.00	+0.66%	3,930

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 14/08/2026			5-day change	1st Jan Change
1,705.00 ^KRW	+0.77%		+1.85%	-65.90%

06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Market Cap	18.82B 13.31M 11.49M 10.78M 9.82M 18.46M 1.27B 18.72M 126M 49.52M 638M 49.98M 48.89M 2.12B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	1.63B 1.15M 993K 932K 849K 1.6M 110M 1.62M 10.93M 4.28M 55.13M 4.32M 4.23M 183M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
05-07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
04-27	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
04-27	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
03-20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-15	APTOCROM Inc. announces Annual dividend	CI
11-13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/08/25	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
24/06/25	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
21/05/25	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	+0.77%
1 week	+1.85%
Current month	+2.34%
1 month	+0.35%
3 months	-44.28%
6 months	-57.59%
Current year	-65.90%

APTOCROM Inc. Share Price

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,620	1,740
1 month	1,430	1,740
Current year	1,430	5,400
1 year	1,430	8,740
3 years	1,430	42,300
5 years	1,430	113,000
10 years	1,430	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	22/03/2022
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	22/03/2022
Jae-Seob Kim BRD	Director/Board Member	63	09/01/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+0.77%	+1.85%	-79.11%	-95.48%	13.31M
ELI LILLY AND COMPANY	+1.01%	-3.23%	+70.78%	+121.73%	1,052B
JOHNSON & JOHNSON	+0.64%	+0.21%	+48.86%	+50.78%	627B
ABBVIE INC.	+0.35%	+0.83%	+21.03%	+66.66%	441B
ROCHE HOLDING AG	+0.28%	-4.56%	+39.10%	+38.05%	349B
NOVARTIS AG	+0.78%	-2.68%	+23.13%	+37.32%	287B
ASTRAZENECA PLC	+0.87%	-3.59%	-1.52%	+7.12%	241B
AMGEN INC.	+0.23%	-0.25%	+42.22%	+57.73%	224B
NOVO NORDISK A/S	-0.78%	-4.49%	-15.86%	-54.13%	202B
GILEAD SCIENCES, INC.	+0.27%	+4.30%	+17.62%	+81.41%	172B
Average	+0.33%	-0.58%	+16.63%	+31.12%	359.52B
Weighted average by Cap.	+0.48%	-0.63%	+39.95%	+64.25%

	2024	2025
Net sales	16.4B 11.6M 10.01M 9.39M 8.56M 16.09M 1.11B 16.31M 110M 43.16M 556M 43.55M 42.61M 1.85B	9.81B 6.94M 5.99M 5.62M 5.12M 9.62M 663M 9.76M 65.86M 25.81M 332M 26.04M 25.48M 1.11B
Net income	-28.09B -19.87M -17.15M -16.09M -14.66M -27.56M -1.9B -27.94M -189M -73.93M -952M -74.6M -72.99M -3.17B	-5.56B -3.93M -3.39M -3.18M -2.9M -5.45M -376M -5.53M -37.33M -14.63M -188M -14.76M -14.44M -627M
Net Debt	-25.07B -17.73M -15.31M -14.36M -13.08M -24.59M -1.7B -24.93M -168M -65.97M -849M -66.57M -65.13M -2.83B	-17.19B -12.16M -10.5M -9.85M -8.97M -16.87M -1.16B -17.1M -115M -45.24M -583M -45.65M -44.67M -1.94B